Japanese dermatology specialist Maruho Co. Ltd and drug discovery firm 4SC AG have terminated their development agreement related to 4SC’s blockers of Kv1.3 ion channels, which are required for maintenance of activation of T cells. 4SC reacquired all rights to the preclinical development programme, which was aimed at specifically calm down chronically stimulated memory T-cell populations with Kv1.3highIK-1low phenotype as a strategy to treat autoimmune diseases.
The companies gave no reasons for the end of their collaboration. 4SC’s CEO Jason Loveridge, however, said that "a good deal of progress has been made" in the three years of the collaboration. Under the terminated colloaboration, 4SC had granted Maruho the exclusive worldwide rights to develop and commercialise two classes of these blockers in exchange for US-$103 in milestones plus royalties.
Mabion to licence COVID-19 jab from Vaxine Pty Ltd
Latest NewsPolish Mabion SA and Australian Vaxine Pty Ltd to develop Covax-19
4SC and Maruho end collaboration on Kv1.3 blockers
Latest NewsJapanese dermatology specialist Maruho Co. Ltd and drug discovery firm 4SC AG have terminated their development agreement related to 4SC’s blockers of Kv1.3 ion channels, which are required for maintenance of activation of T cells. 4SC reacquired all rights to the preclinical development programme, which was aimed at specifically calm down chronically stimulated memory T-cell populations with Kv1.3highIK-1low phenotype as a strategy to treat autoimmune diseases.
The companies gave no reasons for the end of their collaboration. 4SC’s CEO Jason Loveridge, however, said that "a good deal of progress has been made" in the three years of the collaboration. Under the terminated colloaboration, 4SC had granted Maruho the exclusive worldwide rights to develop and commercialise two classes of these blockers in exchange for US-$103 in milestones plus royalties.
MiNA Therapeutic bags £23m financing
Latest NewsRNA therapeutics specialist MiNA Therapeutics plc has secured £23m in a Series A financing to push development its first-in-class small activating RNA (saRNA) candidates.
French Valneva appoints new CMO
AppointmentsIn October Juan Carlos Jaramillo will take over the business from Wolfgang Bender as new Chief Medical Officer and member of the Valneva Management Board.
Vaccine developers unite to stand with science
Latest NewsNine CEOs of COVID-19 vaccines have assured that safety of vaccinated individuals remains their top priority in development of the first COVID-19 vaccines.
EuropaBio with new Chairman
AppointmentsAndrew Topen is the new Chairman of the European Association for Bioindustries EuropaBio.
Scope Fluidics gets EIB loan for infection diagnostics
Latest NewsThe European Investment Bank has lend up to €10m to Polish microbial diagnostics specialist Scope Fluidics AS.
COVID-19: Roche AG launches antigen rapid test
Latest NewsRoche has announced to launch a SARS-CoV-2 point-of-care antigen test this month co-developed with SD Biosensor Inc. (South Korea).
Unilever to replace fossil carbon in cleaning products
Latest NewsUnilever has announced to invest €1bn globally to eliminate fossil fuels as a source of carbon in its cleaning products by 2030.
Interview: Neciah Dorh, CEO, FluoretiQ
Background15min to detect bacterial infections – that’s what British diagnostics company FluoretiQ Ltd is offering in the fight against antimicrobial resistance. A short interview with CEO Neciah Dorh.